Pharmacokinetics of Didanosine and Drug Resistance Mutations in Infants Exposed to Zidovudine During Gestation or Postnatally and Treated With Didanosine or Zidovudine in the First Three Months of Life

Division of Infectious Diseases, Columbia University, New York, New York, United States
The Pediatric Infectious Disease Journal (Impact Factor: 2.72). 06/2005; 24(6):503-9. DOI: 10.1097/01.inf.0000164787.63237.0b
Source: PubMed


There are limited numbers of drugs that are available in formulations that are appropriate for neonates and few studies assessing resistance among infants born to human immunodeficiency virus (HIV)-infected women.
Pharmacokinetics and tolerance of didanosine (ddI) were determined for infants < or =120 days of age. Infants received at least 24 hours of zidovudine (ZDV) treatment, followed by a single ddI dose and pharmacokinetic sampling. The target area under the concentration-time curve (AUC) was between 2.5 and 5.0 microM . hour. Toxicity and drug resistance mutations were assessed at baseline and follow-up times.
The initial ddI pharmacokinetic dosing of 50 mg/m for infants >28 days of age achieved a median AUC0-infinity of 2.8 microM . hour. For infants < or =28 days of age, the target AUC was achieved after dose escalation from 25 mg/m (median AUC0-infinity, 1.4 microM . hour) to 50 mg/m (median AUC0-infinity, 5.40 microM . hour). At baseline, 25% of infected infants had drug resistance mutations (9 of 44 to ZDV and 2 of 44 to ddI). Resistance mutations were present for 29% of infants (5 of 17 infants) with in utero ZDV exposure and 25% (8 of 32 infants) with prior ZDV treatment. The most common ZDV mutation noted at baseline was the T215Y/F (n = 7) mutation; 2 of these infants also had the M41L mutation, which is associated with high level ZDV resistance. No prior exposure was noted for the 2 infants with ddI resistance, which indicates possible perinatal transmission of ddI-resistant virus to these infants.
A dose of 50 mg/m is the appropriate ddI dose for infants <120 days of age and is a safe treatment for newborns when used in combination with ZDV. Genotypic resistance occurs frequently among infected infants exposed to ZDV during gestation or postnatally, which suggests that resistance testing should be considered for infants with newly diagnosed HIV infection.

2 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Half of the ARV agents available worldwide have paediatric approval, but many are without ideal paediatric formulations. Pharmacokinetic differences in paediatric populations require careful attention to dosing and concomitant therapies. Importantly, ARV therapy can be limited by short-term and long-term toxicity and drug interactions. Low-cost, sustained and consistent access to ARV therapy is necessary to combat the HIV epidemic. For optimal response > 90 - 95% adherence to ARVs is required. This requires that extensive education and support resources be provided in addition to the ARV medications themselves. Paediatric patients receiving ARV therapy require ongoing monitoring to ensure tolerability, dose adjustments with advancing age, acceptability and therapeutic success.
    11/2005; 6(4).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antiretroviral (ARV) therapy has been shown to achieve high therapeutic efficacy in treating pediatric HIV disease. The delivery of affordable, child friendly, and easy to store and administer ARV drugs is key to the successful management of HIV in children. In recent years, significant progress has been made in scaling up the access to pediatric ARV therapy among children worldwide. Despite the improved ARV drug access, multiple challenges remain concerning palatability and efficient delivery of ARV drugs to children from infancy into adolescence. Data are limited regarding developmental changes in pharmacokinetics of individual ARV drugs, and pediatric and adult fixed-dose combinations. This review provides a practical discussion regarding the pharmacokinetics of ARV agents in pediatric HIV-infected patients, as well as the practical challenges of currently available formulations, such as palatability of liquid formulations, challenges of crushing tablets, and using adult and pediatric fixed-dose combinations.
    Paediatric Drugs 06/2011; 13(3):175-92. DOI:10.2165/11587300-000000000-00000 · 1.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antiretroviral therapy (ART) in pregnant women represents a unique combination of therapy and prophylaxis of HIV infection. Until the global epidemic of HIV and the discovery of efficient prevention of perinatal transmission through ART, the world has not witnessed a pharmacologic intervention of such a scale during pregnancy and delivery. The use of ART in pregnancy creates unique challenges in delivering therapeutic agents, targeting the HIV virus in both the pregnant woman and her unborn child, throughout dramatic changes in their physiologic state. With an increased complexity of perinatal ART and the introduction of novel agents into clinical practice, a better understanding of the pharmacokinetics (PK) and pharmacodynamics of ARV drugs is crucial for the safe and most effective use of ARV drugs in women during pregnancy and infants in the first months of life. While PK studies are already difficult to perform during pregnancy, they are particularly challenging in women with HIV infection due to multiple social, economic and cultural constrains. In this paper we provide an overview of published studies of ART disposition during pregnancy, labor, breastfeeding and in the newborn infant after delivery.
    Current Drug Metabolism 03/2012; 13(6):744-59. DOI:10.2174/138920012800840365 · 2.98 Impact Factor
Show more